31 studies found for:    BIBF 1120 | Phase 2
Show Display Options
Rank Status Study
1 Completed BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: BIBF 1120;   Drug: mFolfox;   Drug: Bevacizumab;   Drug: mFolfox 6;   Drug: bevacizumab
2 Not yet recruiting A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
Conditions: Small Cell Lung Cancer;   Platinum-sensitive
Intervention: Drug: BIBF1120
3 Recruiting Nintedanib(BIBF1120) in Thyroid Cancer
Conditions: Medullary Thyroid Cancer (MTC);   Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Nintedanib;   Drug: Placebo
4 Active, not recruiting Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
5 Recruiting NOA-12: BIBF1120 and R-RT in Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: BIBF 1120;   Radiation: radiotherapy
6 Active, not recruiting Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120;   Drug: sunitinib
7 Not yet recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
8 Active, not recruiting Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Condition: Breast Cancer
Interventions: Drug: BIBF + Paclitaxel;   Drug: Paclitaxel
9 Recruiting BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: BIBF 1120
10 Completed A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: BIBF 1120;   Drug: BIBW 2992;   Drug: Sequential BIBF 1120 + BIBW 2992
11 Recruiting ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Condition: Uterine Cervical Neoplasms
Interventions: Drug: Nintedanib;   Drug: Placebo
12 Recruiting Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: vargatef;   Drug: placebo
13 Completed Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Condition: Pulmonary Fibrosis
Interventions: Drug: low dose BIBF1120 once daily;   Drug: low dose BIBF 1120 twice daily;   Drug: intermediate dose BIBF 1120 twice daily;   Drug: high dose BIBF 1120 twice daily;   Drug: placebo
14 Completed Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Placebo;   Drug: BIBF 1120
15 Recruiting Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage III Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: nintedanib;   Other: laboratory biomarker analysis
16 Completed Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 ES low dose;   Drug: BIBF 1120 ES high dose;   Drug: Placebo to BIBF 1120 ES
17 Recruiting Nintedanib (BIBF 1120) in Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Nintedanib;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Placebo
18 Terminated Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Doxil (Pegylated Liposomal Doxorubicin);   Drug: BIBF 1120
19 Recruiting BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer;   Small Cell Lung Cancer Recurrent
Intervention: Drug: BIBF 1120
20 Active, not recruiting Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: triple kinase inhibitor BIBF1120

Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results
Indicates status has not been verified in more than two years